Ipsen at a glance

Innovation for

patient care

Press releases

16 April 2015

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

08 April 2015

Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

YOU ARE ON IPSEN'S CORPORATE WEBSITE

The corporate website is governed by the International Federation of Pharmaceutical Manufacturers & Associations code of practice.
Certain information provided on this website may not be strictly in conformity with the French regulations on advertising.

> Close